Anne-Sophie Debrie

Anne-Sophie Debrie

Auto-generated profile, based on publicly available information

Anne-Sophie Debrie

INSERM U629, Lille, France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PSPhilip Supply
Philip Supply
MMMichael Marceau
Michael Marceau
SMSophie Mangenot
Sophie Mangenot
DRDavid Roche
David Roche
CRCarine Rouanet
Carine Rouanet
RBRoland Brosch
Roland Brosch
Roland Brosch and colleagues report whole-genome sequencing of tubercle bacilli with smooth colony morphology, also known as Mycobacterium canetti and/or Mycobacterium prototuberculosis, obtained from humans with tuberculosis from geographically diverse regions. Their comparative genomic analysis with Mycobacterium tuberculosis and other M. tuberculosis complex members identifies extensive recombination and provides insights into the evolution of mycobacteria. The authors also report that tubercle bacilli with smooth colony morphology show reduced persistence and virulence compared to M. tuberculosis strains in infection experiments in mice. Global spread and limited genetic variation are hallmarks of M. tuberculosis, the agent of human tuberculosis. In contrast, Mycobacterium canettii and related tubercle bacilli that also cause human tuberculosis and exhibit unusual smooth colony morphology are restricted to East Africa. Here, we sequenced and analyzed the whole genomes of five representative strains of smooth tubercle bacilli (STB) using Sanger (4–5× coverage), 454/Roche (13–18× coverage) and/or Illumina DNA sequencing (45–105× coverage). We show that STB isolates are highly recombinogenic and evolutionarily early branching, with larger genome sizes, higher rates of genetic variation, fewer molecular scars and distinct CRISPR-Cas systems relative to M. tuberculosis. Despite the differences, all tuberculosis-causing mycobacteria share a highly conserved core genome. Mouse infection experiments showed that STB strains are less persistent and virulent than M. tuberculosis. We conclude that M. tuberculosis emerged from an ancestral STB-like pool of mycobacteria by gain of persistence and virulence mechanisms, and we provide insights into the molecular events involved.

7 July 2006 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NMNathalie Mielcarek
Nathalie Mielcarek
ADAnne-Sophie Debrie
Anne-Sophie Debrie
DRDominique Raze
Dominique Raze
JBJulie Bertout
Julie Bertout
CRCarine Rouanet
Carine Rouanet
CLCamille Locht
Camille Locht
Pertussis is still among the principal causes of death worldwide, and its incidence is increasing even in countries with high vaccine coverage. Although all age groups are susceptible, it is most severe in infants too young to be protected by currently available vaccines. To induce strong protective immunity in neonates, we have developed BPZE1, a live attenuated Bordetella pertussis strain to be given as a single-dose nasal vaccine in early life. BPZE1 was developed by the genetic inactivation or removal of three major toxins. In mice, BPZE1 was highly attenuated, yet able to colonize the respiratory tract and to induce strong protective immunity after a single nasal administration. Protection against B. pertussis was comparable to that induced by two injections of acellular vaccine (aPV) in adult mice, but was significantly better than two administrations of aPV in infant mice. Moreover, BPZE1 protected against Bordetella parapertussis infection, whereas aPV did not. BPZE1 is thus an attractive vaccine candidate to protect against whooping cough by nasal, needle-free administration early in life, possibly at birth. Although vaccination has strongly reduced the incidence of whooping cough in many countries, this disease still causes approximately 300,000 deaths per year, mainly in young children that are not fully vaccinated. Efficient protection against pertussis requires at least three vaccine doses and is not achieved before the age of 6 mo. A new strategy to induce strong protective immunity in neonates is to mimic as closely as possible natural infection without inducing the disease, by the use of a live attenuated B. pertussis strain to be given as a single-dose nasal vaccine. The authors examined in the mouse model the efficacy of a genetically attenuated strain, BPZE1. This strain colonizes the mouse respiratory tract, but appears to be highly attenuated as evidenced by histopathological studies. In addition, a single nasal administration of this strain protects against challenge with virulent B. pertussis better than two administrations of acellular vaccine in infant mice. Moreover, BPZE1 provides protection against infection with Bordetella parapertussis responsible for a milder pertussis-like syndrome, which was not seen after vaccination with acellular vaccine. These results show that BPZE1 could be an efficient, single-dose nasal vaccine to protect early in life against whooping cough.

15 August 2007 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JHJean-Michel Hougardy
Jean-Michel Hougardy
SPSammy Place
Sammy Place
MHMarc Hildebrand
Marc Hildebrand
ADAnnie Drowart
Annie Drowart
ADAnne-Sophie Debrie
Anne-Sophie Debrie
FMFrançoise Mascart
Françoise Mascart
Rationale: Tuberculosis (TB) remains a leading cause of death, and the role of T-cell responses to control Mycobacterium tuberculosis infections is well recognized. Patients with latent TB infection develop strong IFN-γ responses to the protective antigen heparin-binding hemagglutinin (HBHA), whereas patients with active TB do not. Objectives: We investigated the mechanism of this difference and evaluated the possible involvement of regulatory T (Treg) cells and/or cytokines in the low HBHA T-cell responses of patients with active TB. Methods: The impact of anti–transforming growth factor (TGF)-β and anti–IL-10 antibodies and of Treg cell depletion on the HBHA-induced IFN-γ secretion was analyzed, and the Treg cell phenotype was characterized by flow cytometry. Measurements and Main Results: Although the addition of anti–TGF-β or anti–IL-10 antibodies had no effect on the HBHA-induced IFN-γ secretion in patients with active TB, depletion of CD4+CD25highFOXP3+ T lymphocytes resulted in the induction by HBHA of IFN-γ concentrations that reached levels similar to those obtained for latent TB infection. No effect was noted on the early-secreted antigen target–6 or candidin T-cell responses. Conclusions: Specific CD4+CD25highFOXP3+ T cells depress the T-cell–mediated immune responses to the protective mycobacterial antigen HBHA during active TB in humans.

8 August 2004 in Nature Medicine
Verified
Journal Article
Open access
PDF file
STStéphane Temmerman
Stéphane Temmerman
KPKevin Pethe
Kevin Pethe
MPMarcela Parra
Marcela Parra
SASylvie Alonso
Sylvie Alonso
CRCarine Rouanet
Carine Rouanet
CLCamille Locht
Camille Locht
Although post-translational modifications of protein antigens may be important componenets of some B cell epitopes, the determinants of T cell immunity are generally nonmodified peptides. Here we show that methylation of the Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA) by the bacterium is essential for effective T cell immunity to this antigen in infected healthy humans and in mice. Methylated HBHA provides high levels of protection against M. tuberculosis challenge in mice, whereas nonmethylated HBHA does not. Protective immunity induced by methylated HBHA is comparable to that afforded by vaccination with bacille Calmette et Guérin, the only available anti-tuberculosis vaccine. Thus, post-translational modifications of proteins may be crucial for their ability to induce protective T cell-mediated immunity against infectious diseases such as tuberculosis.

8 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RTRigmor Thorstensson
Rigmor Thorstensson
BTBirger Trollfors
Birger Trollfors
NANabil Al-Tawil
Nabil Al-Tawil
MJMaja Jahnmatz
Maja Jahnmatz
JBJakob Bergström
Jakob Bergström
CLCamille Locht
Camille Locht
Acellular pertussis vaccines do not control pertussis. A new approach to offer protection to infants is necessary. BPZE1, a genetically modified Bordetella pertussis strain, was developed as a live attenuated nasal pertussis vaccine by genetically eliminating or detoxifying 3 toxins. We performed a double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally for the first time to human volunteers, the first trial of a live attenuated bacterial vaccine specifically designed for the respiratory tract. 12 subjects per dose group received 103, 105 or 107 colony-forming units as droplets with half of the dose in each nostril. 12 controls received the diluent. Local and systemic safety and immune responses were assessed during 6 months, and nasopharyngeal colonization with BPZE1 was determined with repeated cultures during the first 4 weeks after vaccination. Colonization was seen in one subject in the low dose, one in the medium dose and five in the high dose group. Significant increases in immune responses against pertussis antigens were seen in all colonized subjects. There was one serious adverse event not related to the vaccine. Other adverse events were trivial and occurred with similar frequency in the placebo and vaccine groups. BPZE1 is safe in healthy adults and able to transiently colonize the nasopharynx. It induces immune responses in all colonized individuals. BPZE1 can thus undergo further clinical development, including dose optimization and trials in younger age groups. ClinicalTrials.gov NCT01188512

1 February 2003 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FMFrançoIse Mascart
FrançoIse Mascart
VVVirginie Verscheure
Virginie Verscheure
AMAnne Malfroot
Anne Malfroot
MHMarc Hainaut
Marc Hainaut
DPDenis PiérArd
Denis PiérArd
CLCamille Locht
Camille Locht
Neonatal immaturity of the immune system is currently believed to generally limit the induction of immune responses to vaccine Ags and to skew them toward type 2 responses. We demonstrated here that Bordetella pertussis infection in very young infants (median, 2 mo old) as well as the first administration of whole-cell pertussis vaccine induces B. pertussis Ag-specific IFN-γ secretion by the PBMC of these infants. IFN-γ was secreted by both CD4+ and CD8+ T lymphocytes, and the levels of Ag-induced IFN-γ secretion did not correlate with the age of the infants. Appearance of the specific Th-1 cell-mediated immunity was accompanied by a general shift of the cytokine secretion profile of these infants toward a stronger Th1 profile, as evidenced by the response to a polyclonal stimulation. We conclude that the immune system of 2-mo-old infants is developmentally mature enough to develop Th1 responses in vivo upon infection by B. pertussis or vaccination with whole-cell pertussis vaccines.